ReviewVaccines2014
Schistosome Vaccine Adjuvants in Preclinical and Clinical Research.
Review in Vaccines, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Pre-clinical studies of Schistosoma mansoni vaccines: A scoping review.PLoS neglected tropical diseases · 2025Article
- Article
- Enhancing vaccine effectiveness in the elderly to counter antibiotic resistance: The potential of adjuvants via pattern recognition receptors.Human vaccines & immunotherapeutics · 2024Review
- Validation of Multi-epitope Peptides Encapsulated in PLGA Nanoparticles Against Influenza A Virus.Pharmaceutical research · 2023Article
- The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections.Clinical microbiology reviews · 2023Review
- Advances in Infectious Disease Vaccine Adjuvants.Vaccines · 2022Review
- Vaccines for Human Schistosomiasis: Recent Progress, New Developments and Future Prospects.International journal of molecular sciences · 2022Review
- A Recombinant Protein SARS-CoV-2 Candidate Vaccine Elicits High-titer Neutralizing Antibodies in Macaques.Research square · 2021Article
- Immunoinformatics Design of Multi-Epitope Peptide-Based Vaccine AgainstFrontiers in immunology · 2021Article
- "A recombinant protein SARS-CoV-2 candidate vaccine elicits high-titer neutralizing antibodies in macaques."bioRxiv : the preprint server for biology · 2020Article
- Fifteen Years of Sm-p80-Based Vaccine Trials in Nonhuman Primates: Antibodies From Vaccinated Baboons Confer ProtectionFrontiers in immunology · 2020Article
- A Multiple Antigen Peptide Vaccine Containing CD4Journal of immunology research · 2020Article
- Schistosomiasis vaccines: where do we stand?Parasites & vectors · 2016Review
- Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems.Parasites & vectors · 2016Article
- Do schistosome vaccine trials in mice have an intrinsic flaw that generates spurious protection data?Parasites & vectors · 2016Review
- Why the radiation-attenuated cercarial immunization studies failed to guide the road for an effective schistosomiasis vaccine: A review.Journal of advanced research · 2015Review
- Suppression of the Insulin Receptors in Adult Schistosoma japonicum Impacts on Parasite Growth and Development: Further Evidence of Vaccine Potential.PLoS neglected tropical diseases · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is currently no vaccine available for human use for any parasitic infections, including the helminth disease, schistosomiasis. Despite many researchers working towards this goal, one of the focuses has been on identifying new antigenic targets. The bar to achieve protective efficacy in humans was set at a consistent induction of 40% protection or better by the World Health Organisation (WHO), and although this is a modest goal, it is yet to be reached with the six most promising schistosomiasis vaccine candidates (Sm28GST, IrV5, Sm14, paramyosin, TPI, and Sm23). Adjuvant selection has a large impact on the effectiveness of the vaccine, and the use of adjuvants to aid in the stimulation of the immune system is a critical step and a major variable affecting vaccine development. In addition to a comprehensive understanding of the immune system, level of protection and the desired immune response required, there is also a need for a standardised and effective adjuvant formulation. This review summarises the status of adjuvants that have been or are being employed in schistosomiasis vaccine development focusing on immunisation outcomes at preclinical and clinical stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.